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Abstract
Background: We aimed to assess whether gross tumor volume (GTV) determined by fusion of contrast-enhanced
computerized tomography (CT) and 18F-fluoro-deoxy-D-glucose positron emission tomography-CT (FDG-PET-CT)
based radiotherapy planning could predict outcomes, namely overall survival (OS), local-regional progression-free
survival (LRPFS), and progression-free survival (PFS) in cases with locally advanced pancreas cancer (LAPC) treated
with definitive concurrent chemoradiotherapy.
Methods: A total of 30 patients with histological proof of LAPC underwent 50.4 Gy (1.8 Gy/28 fractions) of
radiotherapy concurrent with continuously infused 5-FU followed by 4 to 6 courses of maintenance gemcitabine.
Target volume delineations were performed on FDG-PET-CT-based RTP. Patients were stratified into 2 groups: GTV
lesser (GTVL) versus greater (GTVG) than cut off value determined by receiver operating characteristic (ROC) analysis,
and compared in terms of OS, LRPFS and PFS.
Results: Median GTV delineated according to the FDG-PET-CT data was 100.0 cm
3. Cut off GTV value determined
from ROC curves was 91.1 cm
3. At a median follow up of 11.2 months, median OS, LRPFS and PFS for the entire
population were 10.3, 7.8 and 5.7 months, respectively. Median OS, LRPFS and PFS for GTVL and GTVG cohorts were
16.3 vs. 9.5 (p = 0.005), 11.0 vs. 6.0 (p = 0.013), and 9.0 vs. 4.8 months (p = 0.008), respectively.
Conclusions: The superior OS, LRPFS and PFS observed in GTVL patients over GTVG ones suggests a potential for
FDG-PET-CT-defined GTV size in predicting outcomes of LAPC patients treated with definitive C-CRT, which needs
to be validated by further studies with larger cohorts.
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Background
Concurrent chemoradiotherapy (C-CRT) has been a
well-established treatment option for patients with
locally-advanced pancreas cancer (LAPC), which consti-
tutes approximately one third of pancreatic carcinomas
(PC) [1,2]. In spite of significant improvements in
diagnostic imaging, chemotherapy, and radiotherapy
(RT), outcome in LAPC is still dismal with median over-
all survival (OS) rarely exceeding 1 year even following
aggressive C-CRT [3,4].
Several surgical series have established factors includ-
ing tumor size, status of resection margins, invasion of
vascular and/or adjacent structures, degree of differen-
tiation, performance status, carbohydrate antigen 19-9
and C-reactive protein levels, to affect the outcome in
resectable PC [2]. However, there are only few series
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none -to the best of our knowledge- has specifically
evaluated local/regional tumor burden in terms of gross
tumor volume (GTV) in the era of definitive C-CRT,
which was shown to be highly predictive for local control
(LC), OS and progression-free survival (PFS) in various
primaries including, lung, oral cavity and nasopharynx
[8-11].
In studies by Lemke et al. [12] and Delbeke et al. [13]
functional imaging with 18F-fluoro-deoxyglucose posi-
tron emission tomography (FDG-PET) has been demon-
strated to increase accuracy of PC staging compared to
conventional methods with its higher sensitivity and spe-
cificity. Based on these promising results, and considering
the fact that accurate definition of primary tumor and its
local/regional extensions is the first step of any effort to
improve LC rates with RT, in our earlier comparative
dosimetric study, we demonstrated an average of 29.7%
enlargement in GTV being necessary in 5 out of 14
(35.7%) patients due to detection of additional computer-
ized tomography-(CT) occult lymph node metastases
and/or primary tumor extensions outlined by co-regis-
tered FDG-PET-CT [14]. From thereon, we changed our
routine practice for target volume delineation that was
based solely on contrast-enhanced CT findings, and
began to use fusion of contrast-enhanced CT and FDG-
PET-CT for this purpose in patients with LAPC.
In this study, which involved the first 30 patients of our
on-going phase II study targeting to enrol a total of 120
patients, we investigated whether size of GTV determined
by contrast-enhanced CT/FDG-PET-CT fusion could pre-
dict treatment outcomes, namely OS, local-regional pro-
gression-free survival (LRPFS), and PFS in LAPC patients
treated with C-CRT.
Methods
Patients population
Thirty consecutive patients, referred with histologically
proven diagnosis of surgically unresectable LAPC from
March 2008 to December 2010 were enrolled in this
study. Our institutional definition for technically unre-
sectable PC is to be stage III (T4N0-1 M0) disease, which
is the involvement of celiac axis and/or superior mesen-
teric artery. Disease extent was determined in all patients
with radiological studies and laparotomy or laparoscopy.
Standard radiological studies included contrast-enhanced
abdominal CT, magnetic resonance imaging (MRI) and/
or MR-cholangiopancreaticography (MRCP). All patients
were re-staged via fusion of previous CT images
(obtained ≤ 1w e e kb e f o r eP E T / C Ts c a n s )w i t hF D G -
PET-CT obtained for RTP. All patients underwent
laparoscopic (n = 12) or laparotomic (n = 18) examina-
tion and biopsies for histologic diagnosis of primary
tumor and enlarged/metabolically active regional lymph
nodes and isolated single organ metastasis respecting the
current standard institutional staging procedure for pan-
creatic carcinoma. Patients, who had received che-
motherapy or abdominal irradiation previously, were not
included in the study. The eligibility criteria also included
an age of 18 to 70 years, Eastern Cooperative Oncology
Group (ECOG) performance status (PS) of 0 to 2, pre-
sence of measurable or evaluable lesion, no contraindica-
tion for FDG-PET-CT imaging, an adequate bone
marrow reserve (hemoglobin value of ≥ 10 g/dL, leuco-
cyte of ≥ 4.000 μL, and thrombocyte of ≥ 100.000 μL),
hepatic (aspartate aminotransferase or alanine amino-
transferase of < 5 times the upper limit) and renal func-
tion (serum creatinine < 2 mg/dL). All patients signed
informed consent, and the study design was approved by
the Institutional Ethical Committee, in accordance with
the Helsinki Declaration and Rules of Good Clinical
Practice.
FDG-PET-CT image registration and radiation treatment
planning
FDG-PET-CT scans were performed according to the
institutional protocol described elsewhere [14]. Areas of
FDG uptake were categorized as malignant based on
location, intensity, shape, size, and visual correlation with
contrast-enhanced CT images to differentiate physiologic
from pathologic uptake.
Image registration and RTP were performed via Eclipse
7.5 (Varian Medical Systems, Palo Alto, CA, USA) RTP
system. The use of standard uptake values (SUV) alone for
determining malignant involvement for delineation is sub-
jective; therefore SUV measurements were not specifically
used alone for delineation. For all 30 patients, two radia-
tion oncologists consensually defined the target volumes,
with the assistance of a nuclear medicine physician, and
contoured the GTV, the planning target volume (PTV),
and the organs at risk (OAR) on the contrast-enhanced
CT/FDG-PET-CT fusion images. While the GTV (primary
and nodal) was delineated on the FDG-PET/CT fusion, all
OAR volumes were contoured from the CT due to inher-
ent difficulty with edge detection in contouring PET
volumes. For each patient, GTV included the primary
tumor (GTVP) and involved lymph nodes (GTVN) appar-
ent on contrast-enhanced CT (short axis ≥ 1.5 cm) and/or
PET images. Those nodes < 1.5 cm were involved in GTV
only if they were judged to be malignant on PET scan.
Based on the literature [15] depicting nearly 1.5 cm move-
ment of pancreas with respiration and considering the
unavailability of motion tracking system and image gui-
dance at our department, PTV was defined by adding 2
cm to GTV at all directions except for intersecting OAR
restrictions to allow for microscopic extension, organ
motion and set-up errors. Elective nodal irradiation was
not permitted in the study.
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A single target volume with no cone down volumes was
intended to be treated. A four-field technique (postero-
anterior, antero-posterior, and laterals) was mandated,
and treatment volumes were defined by using customized
multi-leaf collimators. All patients received the RT proto-
col utilizing 18 MV photon energy linear-accelerators. A
dose of 50.4 Gy (1.8 Gy/fr) was prescribed to encompass
the defined PTV with isodose lines between 95% and
107%. To achieve this, we used dosimetric practice
wedges to modify beams. Dose-volume histograms were
generated for each patient to assess target volume cover-
age and organ at risk doses. The maximum dose limits
for normal tissues were 45 Gy for spinal cord; 50 Gy for
small bowel and stomach; 50 Gy for ≤ one-third, 35 Gy
for two-thirds, and 30 Gy for three-thirds of the liver;
and 20 Gy for at least two-thirds of one functioning
kidney.
All patients received continuously infused 5-FU
(225 mg/m
2/day, 7 days/week) throughout the RT course
(for 5.5 weeks), and additional 4 to 6 courses of mainte-
nance gemcitabine (1,000 mg/m
2 IV over 100 min, days 1
and 8, every 21 days) following C-CRT.
Toxicity assessment
Patients were assessed weekly or if necessary more fre-
quently during C-CRT, every 3 months for the first 2
year, and every 6 months, thereafter. Early and late clini-
cal toxicity was recorded and blood was collected for
haematology and biochemistry assays at each assess-
ment. Toxicity was assessed and scored with the aid of
CTC 3.0 (Common Toxicity Criteria).
Response evaluation and follow-up
Response to treatment was assessed by re-staging FDG-
PET-CT scans, carried out 12 weeks after the completion
of the treatment, according to EORTC-1999 guidelines
[16]. Thereafter, patients were monitored by 8-12 weekly
studies (blood count/chemistry; serum CEA and CA 19-9).
Additional abdominal ultrasound and/or CT, chest CT,
cranial magnetic resonance imaging, and FDG-PET-CT
were used as indicated.
Statistical analyses
The primary aim of this study was to evaluate predictive
usefulness of GTV on clinical outcomes. For this purpose,
we used receiver operating characteristic (ROC) analysis
to determine whether GTV improved discrimination of
outcomes. The ROC analysis represents the area under
the curve (AUC) of sensitivity versus false-positive rate (1-
specificity), and is equivalent to the probability that a pre-
dictive model will assign a higher probability of an event
to subjects who subsequently have an event. Then,
patients were dichotomized into two groups, GTV greater
(GTVG) versus lesser (GTVL) than the cut off value, and
compared in terms of LRPFS, PFS, and OS. LRPFS was
defined as survival without local-regional failure, calcu-
lated as the time between the first day of treatment and
the date of local-regional failure or death/last visit. PFS
and OS were calculated as the time between the first day
of treatment and any type of disease progression, and the
date of death/last visit, respectively. Survival analysis was
performed using the Kaplan-Meier method, and survival
curves were compared with two-sided log-rank tests. P ≤
0.05 was considered statistically significant.
Results
Pretreatment characteristics of all 30 patients enrolled to
the study are as summarized in the Table 1. All cases
received the prescribed doseo fR Tp l u st h es c h e d u l e d
chemotherapy concomitantly.
Median GTV delineated by utilizing the contrast-
enhanced CT/FDG-PET-CT fusion data was 100.0 cm
3
(range, 32.9 cm
3 to 224.3 cm
3). From the ROC analysis,
the best cut-off point was set at 91.1 cm
3 where sensitivity
Table 1 Patient characteristics
Characteristic Value
Age (Years)
Median 57
Range 39-68
Gender (%)
Male 21 (70)
Female 9 (30)
Performance Status (%)
ECOG 0-1 23 (76.7)
ECOG 2 7 (23.3)
Location of Tumor (%)
Head 23 (76.7)
Body 7 (23.3)
Clinical Stage (%)
T4N0 13 (43.3)
T4N1 17 (56.7)
SUVmax
Median 14.5
Range 6.2-22.6
GTV (cm
3)
Median 100
Range 32.3-224.3
GTVP (cm
3)
Median 93.4
Range 32.3-205.1
GTVN (cm
3)
Median 7.7
Range 0-19.2
Abbreviations: ECOG Eastern cooperative oncology group; GTV gross tumor
volume; GTVN nodal gross tumor volume; GTVP primary gross tumor volume;
SUV standard uptake value
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area under the ROC curve was 77.7. In 13 cases (43.3%),
GTV was lower than 91.1 cm
3.
At a median follow up of 11.2 months (range, 4.6 to 25.8
months), 23 out of 30 evaluable cases (76.7%) died. Six
cases were alive with no disease progression, 4 of whom
were from the GTVL group while remaining one was still
alive with hepatic metastases. Median follow up was 14.1
months (range, 6.9 to 25.8 months) for GTVL and 9.5
months (range, 4.6 to 25.3 months) for GTVG.M e d i a n
OS, LRPFS, and PFS for the entire population were 10.3
months (95% CI: 9.3 to 11.3 months), 7.8 months (95% CI:
5.8 to 9.8 months), and 5.7 months (95% CI: 4.6 to 6.7
months), respectively (Figure 1).
Comparisons of survival data by Log-rank test revealed
that patients in group GTVL had significantly longer OS,
LRPFS, and PFS than those in GTVG (Figure 2) (p = 0.005,
0.013 and 0.008, respectively). Corresponding median OS,
LRPFS, and PFS for the cohorts GTVL versus GTVG were
16.3 [95% CI, 11.6 to 21.0] versus 9.5 (95% CI, 8.0 to 11.0),
11.0 (95% CI, 2.6 to 19.4) versus 6.0 months (95% CI, 4.1
to 7.9), and 9.0 (95% CI, 0.8 to 17.2) versus 4.8 (95% CI,
3.1 to 6.5), respectively. Results of univariate analyses for
OS, LRPFS, and PFS were given in Table 2.
During follow-up 24 (80%) patients relapsed. Initial fail-
ure site was distant in 21 (70%) and local in 3 (10%)
patients. The latter 3 patients also subsequently developed
distant metastases during their follow up. Details of initial
recurrence pattern according to the GTV groups are sum-
marized in Table 3. Eventually, 16 (53.3%) patients devel-
oped infield recurrences with accompanying distant
metastases. No isolated marginal or regional failure was
reported as an initial or ultimate site of disease
progression.
Rates of acute toxicities experienced in the study are
listed in Table 4. In general, all 30 patients were able to
tolerate the C-CRT with no Grade 4/5 acute toxicity.
Unplanned treatment breaks was mandated in 4 patients
(13.3%) with an average of 3.8 days (range; 2 to 6 days),
due to grade 3 toxicities; diarrhea in 2, leukopenia in 1,
and vomiting in 1 patient. Because of Grade 3 diarrhea
refractory to conventional loperamide and Grade 3 leuko-
penia, hospitalization was needed in 2 respective patients.
However, all 4 patients were able to complete the planned
C-CRT course after symptomatic and supportive treat-
ment. At long-term, 3 patients (10.0%) developed symp-
toms of grade 3 gastric outlet obstruction at median 5.1
months (range; 3.1 to 8.7 months) after completion of C-
CRT. Although late toxicity cannot be excluded as a
cause, because of simultaneous evidence of disease pro-
gression in 2 patients at 4.4 and 7.1 months, progressive
disease was probably associated with the symptoms in
these two patients. Two additional (6.6%) patients experi-
enced grade 2 gastric ulcer at 10.6 and 14.7 months,
respectively, which were successfully managed with appro-
priate medication. No patients developed liver or renal
dysfunction attributed to this C-CRT protocol.
Discussion
We have investigated the predictive utility of GTV deli-
neated by utilizing co-registered contrast-enhanced CT/
FDG-PET-CT on outcomes in patients with LAPC trea-
ted with definitive C-CRT, and demonstrated that
patients with smaller GTVs had significantly better OS,
LRRFS and PFS compared to larger counterparts.
One of the reasons triggering our project is the impact
of the size of the primary pancreatic tumors [17], which
has been well-established in large surgical series of resect-
able PC demonstrating a better outcome with smaller
sizes [18-20]. In their series, Birk et al. [18] and Sohn et al.
[19] respectively demonstrated that patients with tumors <
2 and < 3 cm had significantly superior outcomes com-
pared to those with 2-4 and ≥ 3 cm. In another study of
1697 patients from Johns Hopkins Hospital, de Jong et al.
[20] also evaluated the impact of tumor size on survival
following pancreaticoduodenectomy, and showed that 5-
year OS was inversely proportional to tumor size (≤ 2 cm:
28.8% vs. 2-5 cm: 19.4% vs. ≥ 5 cm: 14.2%, p < 0.001), and
that the size correlated with the risk of other adverse fac-
tors, with larger tumors being more likely to be associated
with nodal disease and poor differentiation (p < 0.05).
Although tumor size at largest dimension has been
addressed in a limited number of studies [21-24], to the
best of our knowledge, the impact of three dimensional
local/regional tumor burden expressed as GTV on outcome
Figure 1 Survival curves for whole study population. Solid line:
Overall survival (OS); Dashed line: Progression-free survival (PFS);
Doted line: Local-regional progression-free survival (LRPFS).
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C-CRT has not been formally evaluated yet. In this respect,
although two studies appeared to directly evaluate prognos-
tic utility of the GTV size on outcome in LAPC patients
[25,26], our study differs from them in significant aspects.
In the first study, Rwigema et al. [25] successfully treated a
group of LAPC patients including primary, recurrent,
resected but margin positive and metastatic disease with
stereotactic body radiotherapy (SBRT). This was a true
volumetric study similar to one presented here, and found
15 mL as a significant volumetric cut point for survival dif-
ference. In the second study reported recently, Bjerregaard
et al. [26] evaluated the impact of GTV on outcomes of
initially unresectable 176 patients with LAPC. In this
study, the authors chose to group patients by 25 cm
3
increments in GTV, and reported a survival advantage
favoring the patients with smaller GTVs. However,
although their results are inl i n ew i t ho u r s ,t h e r ea r e
Figure 2 Comparative survival analyses between GTVL and GTVG cohorts. A: Overall Survival (OS); B: Local Regional Progression-free Survival
(LRPFS), C: Progression-free Survival (PFS);. Solid line: GTVL; Dashed line: GTVG.
Table 2 Univariate analyses for survival
Characteristics N Median OS P Median LRPFS P Median PFS P
Months (95%CI) Months (95%CI) Months (95%CI)
GTV
GTVL 13 16.3 (11.6-21.0) 0.005 11.0 (2.6-19.4) 0.013 9.0 (0.8-17.2) 0.008
GTVG 17 9.5 (8.0-11.0) 6.0 (4.1-7.9) 4.8 (3.1-6.5)
GTVN -
< Median 15 13.2 (8.2-18.2) 0.085 9.8 (7.3-12.3) 0.18 8.4 (4.9-11.9) 0.086
≥ Median 15 9.5 (7.511.5) 6.0 (3.3-8.7) 4.8 (3.2-6.4)
Nodal status
N0 13 13.2 (7.8-18.6) 0.25 9.8 (7.5-12.1) 0.36 8.4 (5.2-11.6) 0.25
N1 17 9.8 (7.8-11.8) 6.1 (4.1-8.1) 4.8 (3.1-6.5)
Age
< Median 14 10.5 (7.2-13.8) 0,99 7.6 (6.1-9.1) 0.97 5.7 (4.6-6.8) 0.92
≥ Median 16 9.8 (9.0-10.6) 7.8 (2.5-13.1) 5.7 (0.8-10.6)
Gender
Male 21 10.3 (9.0-11.6) 0.86 7.6 (6.3-8.9) 0.52 5.7 (4.5-6.9) 0.89
Female 9 10.3 (8.8-11.8) 10.3 (3.0-17.6) 7.3 (2.6-12.0)
ECOG
0-1 23 10.3 (9.2-11.4) 0.61 8.0 (5.7-10.3) 0.84 5.3 (3.1-7.5) 0.88
2 7 10.3 (7.7-12.9) 7.6 (6.3-8.9) 7.3 (3.2-11.4)
Location of Tumor
Head 23 10.3 (9.1-11.5) 0.58 7.6 (4.6-10.6) 0.52 5.7 (4.8-6.6) 0.31
Body 7 10.5 (8.7-12.3) 8.7 (6.4-11.0) 7.3 (2.2-12.4)
Abbreviations: ECOG Eastern cooperative oncology group; GTV gross tumor volume; GTVG gross tumor volume greater than 91.1 (cm
3); GTVL gross tumor volume
lesser than 91.1 (cm
3); GTVN nodal gross tumor volume; LRPFS local regional progression-free survival; OS overall survival; PFS progression-free survival
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one presented here: First, Rwigema and colleagues used
SBRT, which have significantly different radiobiological
effects on tumor tissue than fractionated 3D conformal
RT utilized here, and although our population size is rela-
tively smaller, it is still more homogenous since we did not
include resected, recurrent or metastatic patients. And
second, Bjerregaard and colleagues studied on a highly
heterogeneous study population, which included of 72
T3N0, 71 T3N1, and only 33 T4NX patients. Therefore, it
is difficult to generalize their results for T4N0-1 patients
as they constituted less than 20% of the study population.
Likewise, authors chose to group patients by somehow
arbitrarily specified 25 cm
3 increments in GTV rather
than using possibly more relevant ROC defined cut off
point(s), which creates further difficulties in interpretation
of outcomes.
H e r e i n ,w ep r e f e r r e d3 Dt u m o rv o l u m et od e f i n et h e
tumor burden based on the studies suggesting that one-
dimensional tumor measurements may not be as represen-
tative of tumor size as true volume calculations, especially
in irregularly shaped tumors. In patients with advanced
head and neck cancer, Rudat et al. [27] reported precision
and reliability of the CT based volume measurements by
repeated measurements using irregularly shaped
phantoms. Furthermore, Titola et al. [28] proposed that
one-dimensional volume estimation of irregularly shaped
tumor-like phantoms should be substituted by true com-
puter-based volume calculations.
The GTV, investigated here, has also been found to be
of highly prognostic significance in various tumor sites.
Bradley et al. [8] reported GTV to be a prognostic factor
on both univariate and multivariate analysis in 207
NSCLC patients treated with definitive 3D conformal RT
with or without chemotherapy, while Etiz et al. [9] pointed
out the importance of total tumor volume (< or ≥ 80 cm
3),
defined by combination of primary tumor and nodal
volume, on OS in irradiated inoperable NSCLC patients.
Predictive role of GTV, delineated by 3D conformal RTP,
on outcomes has also been demonstrated in nasopharyn-
geal [10], hypopharyngeal [29,30] and other head and neck
sites [11,31,32]. Likewise, we have studied to pioneer the
importance of well-defined GTV in the setting of LAPC,
and our results revealed that median OS, LRRFS and PFS
for the cohort with GTV lower than and greater than the
ROC-defined 91.1 cm
3 cut value were 14.1 versus 9.5
months, 10.0 versus 6.0 months, and 8.4 versus 4.8
months, respectively (p <0 . 0 5f o re a c h ) .
Based on the assumption that the majority of the benefit
from RT would result from control of the primary tumor,
rather than subclinical disease in lymph nodes, which
could potentially be controlled by the systemic chemother-
apy, as would more distant sites, we did not electively
irradiate uninvolved regional nodes. Supporting this
assumption we observed no isolated regional recurrences,
which is consistent with findings of other studies which
excluded elective nodal irradiation [33,34]. In a phase I
radiation dose escalation study of 34 unresectable or
incompletely resected PC patients treated with RT plus
concurrent gemcitabine, McGinn et al. [33] reduced RT
fields (PTV = GTV + 1 cm) which was even smaller than
our current definition, and observed only 3 (8.8%) regional
failures. The approach excluding the elective irradiation of
regional nodes is further supported by the current radio-
surgical practice in PC [34], which permits only milimetric
margins around the GTV with loco-regional control and
survival rates similar or even better to that of conventional
larger field external beam RT studies. Taken together, we
advocate the idea not to irradiate elective nodal irradiation
at least to an attempt to decrease C-CRT-related toxicity
and possibly to escalate the RT dose to more effective
levels with highly conformal irradiation techniques until
this issue is enlightened with randomized trials.
Conclusions
We have investigated the potential prognostic value of
the GTV delineated by co-registered contrast-enhanced
CT/FDG-PET-CT-based RTP on outcomes in patients
with LAPC. The superior OS, LRPFS and PFS observed
Table 3 Patterns of initial disease progression (N = 30)
Site GTVG (N:17) GTVL (N:13) Overall (N:30)
N (%) N (%) N (%)
Local 3 (17.6) 0 (0) 3 (10)
Regional 0 (0) 0 (0) 0(0)
Distant 13 (76.5) 8 (61.5) 21 (70)
Liver 3 (17.6) 3 (23.1) 6 (20.0)
Peritoneum 2 (11.8) 1 (7.6) 3 (10.0)
Brain 0 (0) 1 (7.6) 1 (3.3)
Multiorgan 8 (47.1) 3 (23.1) 11 (36.7)
Total progression 16 (94.1) 8 (61.5) 24 (80.0)
Abbreviations: GTVG gross tumor volume greater than 91.1 (cm
3); GTVL gross
tumor volume lesser than 91.1 (cm
3)
Table 4 Frequency of Grade 3 acute toxicities
Toxicity Grade
0-1 2 3
Nausea 24 4 2
Vomiting 26 3 1
Diarrhea 24 4 2
Tumor pain 28 2 0
Anorexia 20 10 0
Fatigue 26 3 1
Gastritis 28 2 0
Leukopenia 21 7 2
Anemia 23 6 1
Thrombocytopenia 24 5 1
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for FDG-PET-CT-defined GTV size in predicting out-
comes of LAPC patients treated with definitive C-CRT.
Since it is neither easy nor appropriate to conclude
firmly with findings from such a small study population,
results presented here should better be interpreted with
caution and warrants to be addressed in future trials
with larger cohorts.
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